CM
CSTL icon

Caption Management’s Castle Biosciences CSTL Stock Holding History

Caption Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,600
Closed -$143K – 1346
2024
Q2 		$122K Buy
+5,600
New +$125K ﹤0.01% 1006

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Caption Management's CSTL Position: Q3 2024 in Review

Caption Management sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 5,600 shares — an estimated $143K sold.

Caption Management first reported a position in CSTL in Q2 2024 and held it in 1 quarter. The position peaked at $122K in Q2 2024. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Caption Management reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
  • Caption Management sold 5,600 Castle Biosciences shares in Q3 2024, an estimated $143K.
  • Caption Management first reported a position in Castle Biosciences in Q2 2024 and held it in 1 quarter.
  • Caption Management's Castle Biosciences position peaked at $122K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Caption Management's 13F filing for Q3 2024, filed 14 Nov 2024.